[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 29 of about 29
1. Lee YK, Choi CG, Lee JH: Atypical teratoid/rhabdoid tumor of the cerebellum: report of two infantile cases. AJNR Am J Neuroradiol; 2004 Mar;25(3):481-3
MedlinePlus Health Information. consumer health - MRI Scans.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Atypical teratoid/rhabdoid tumor of the cerebellum: report of two infantile cases.
  • Atypical teratoid/rhabdoid tumor of the CNS is an aggressive infantile neoplasm of uncertain origin.
  • In our two infantile cases, this tumor presented as a bulky cerebellar hemispheric mass with significant mass effect to the fourth ventricle and brain stem.
  • Although the attenuation on CT and signal intensity characteristics at MR imaging of this tumor were similar to those of vermian medulloblastoma, cerebellar hemispheric location and aggressive growth pattern could be considered as different gross morphologic characteristics of this tumor.
  • Despite intensive chemotherapy and radiation therapy, both of our two patients died within 8 months of pathologic diagnosis.
  • [MeSH-major] Cerebellar Neoplasms / congenital. Magnetic Resonance Imaging. Rhabdoid Tumor / congenital. Teratoma / congenital. Tomography, X-Ray Computed
  • [MeSH-minor] Biomarkers, Tumor / analysis. Cerebellum / pathology. Combined Modality Therapy. Dominance, Cerebral / physiology. Fatal Outcome. Female. Follow-Up Studies. Fourth Ventricle / pathology. Humans. Infant. Kidney Neoplasms / congenital. Kidney Neoplasms / diagnosis. Kidney Neoplasms / pathology. Kidney Neoplasms / therapy. Male. Medulla Oblongata / pathology. Neoplasms, Multiple Primary / congenital. Neoplasms, Multiple Primary / diagnosis. Neoplasms, Multiple Primary / pathology. Neoplasms, Multiple Primary / therapy

  • Genetic Alliance. consumer health - Rhabdoid tumor.
  • MedlinePlus Health Information. consumer health - CT Scans.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15037476.001).
  • [ISSN] 0195-6108
  • [Journal-full-title] AJNR. American journal of neuroradiology
  • [ISO-abbreviation] AJNR Am J Neuroradiol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


2. Bourdeaut F, Dufour C, Delattre O: [Rhadboid tumours: hSNF/INI1 deficient cancers of early childhood with aggressive behaviour]. Bull Cancer; 2010 Jan;97(1):37-45
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Transliterated title] Les tumeurs rhabdoïdes : des tumeurs hSNF5/INI1-déficientes précoces et agressives.
  • Rhabdoid tumours are rare aggressive tumours of infancy.
  • The definition classically relies on a characteristic morphology and the inactivation of the hSNF5/INI1 tumour suppressor gene.
  • This entity includes central nervous system tumours (ATRT), renal tumours (RTK) and soft-part tumours.
  • Their rarity and morphological pleomorphism make the diagnosis often challenging.
  • Deletions at the 22q11.2 locus and mutations in hSNF5/INI1 sequence must be investigated in order to confirm the diagnosis and to give insights on a presumable germline mutation.
  • The treatment is based on aggressive chemotherapy, surgery and irradiation.
  • Understanding the role of hSNF5/INI1 within the SWI-SNF complex for the epigenetic regulation of transcription might drive the future targeted therapies.
  • [MeSH-major] Chromosomal Proteins, Non-Histone / genetics. DNA-Binding Proteins / genetics. Gene Silencing. Neoplasm Proteins / genetics. Rhabdoid Tumor / genetics. Transcription Factors / genetics
  • [MeSH-minor] Central Nervous System Neoplasms / diagnosis. Central Nervous System Neoplasms / therapy. Chromosomes, Human, Pair 22 / genetics. Diagnosis, Differential. Genes, Tumor Suppressor. Germ-Line Mutation. Humans. Infant. Kidney Neoplasms / diagnosis. Kidney Neoplasms / therapy. Liver Neoplasms / diagnosis. Liver Neoplasms / therapy. Soft Tissue Neoplasms / diagnosis. Soft Tissue Neoplasms / therapy. Wilms Tumor / diagnosis. Wilms Tumor / therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20080459.001).
  • [ISSN] 1769-6917
  • [Journal-full-title] Bulletin du cancer
  • [ISO-abbreviation] Bull Cancer
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Chromosomal Proteins, Non-Histone; 0 / DNA-Binding Proteins; 0 / Neoplasm Proteins; 0 / SMARCB1 protein, human; 0 / Transcription Factors
  •  go-up   go-down


3. Jones C, Rodriguez-Pinilla M, Lambros M, Bax D, Messahel B, Vujanic GM, Reis-Filho JS, Pritchard-Jones K: c-KIT overexpression, without gene amplification and mutation, in paediatric renal tumours. J Clin Pathol; 2007 Nov;60(11):1226-31
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] c-KIT overexpression, without gene amplification and mutation, in paediatric renal tumours.
  • AIMS: To investigate the presence and prognostic relevance of KIT expression in paediatric renal tumours, and to determine whether receptor overexpression is associated with gene amplification and/or mutation.
  • METHODS: Immunohistochemistry without antigen retrieval for CD117 was carried out on tissue microarrays consisting of 274 Wilms' tumours, 13 clear cell sarcomas of the kidney (CCSK), 10 mesoblastic nephromas (MN), and 7 rhabdoid tumours of the kidney (RTK).
  • RESULTS: Only 8/200 (4.0%) Wilms' tumours exhibited any degree of moderate-strong KIT staining in any of their assessable cell types.
  • This small group of KIT-positive tumours had a shorter time to relapse (p = 0.0044, log-rank test).
  • CONCLUSIONS: KIT overexpression in rare in Wilms' tumours, although does appear to confer a worse prognosis, in particular for patients primarily treated with preoperative chemotherapy.
  • The potential of anti-KIT therapeutic strategies in the treatment of paediatric renal tumours appears to be limited.
  • [MeSH-major] Biomarkers, Tumor / metabolism. Kidney Neoplasms / metabolism. Proto-Oncogene Proteins c-kit / metabolism. Sarcoma, Clear Cell / metabolism. Wilms Tumor / metabolism
  • [MeSH-minor] Antineoplastic Agents. Child. DNA Mutational Analysis. DNA, Neoplasm / genetics. Gene Amplification. Humans. In Situ Hybridization / methods. Neoadjuvant Therapy. Nephrectomy. Prognosis. Survival Analysis. Tissue Array Analysis / methods

  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • MedlinePlus Health Information. consumer health - Wilms Tumor.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Int J Biochem Cell Biol. 1999 Oct;31(10):1037-51 [10582338.001]
  • [Cites] Cell Oncol. 2007;29(5):399-408 [17726262.001]
  • [Cites] N Engl J Med. 2001 Apr 5;344(14):1052-6 [11287975.001]
  • [Cites] J Clin Oncol. 2002 Mar 15;20(6):1692-703 [11896121.001]
  • [Cites] Am J Surg Pathol. 2002 Apr;26(4):486-92 [11914627.001]
  • [Cites] Am J Clin Pathol. 2003 Mar;119(3):325-7 [12645332.001]
  • [Cites] Am J Clin Pathol. 2003 Mar;119(3):339-45 [12645334.001]
  • [Cites] Lab Invest. 2003 Sep;83(9):1293-9 [13679437.001]
  • [Cites] J Clin Oncol. 2003 Dec 1;21(23):4342-9 [14645423.001]
  • [Cites] Lancet Oncol. 2004 Jan;5(1):37-46 [14700607.001]
  • [Cites] J Clin Oncol. 2004 Feb 1;22(3):468-73 [14752069.001]
  • [Cites] J Clin Pathol. 2004 May;57(5):463-6 [15113851.001]
  • [Cites] Cancer Res. 1992 Nov 15;52(22):6139-43 [1384954.001]
  • [Cites] Virchows Arch. 1994;424(2):135-41 [7514077.001]
  • [Cites] J Histochem Cytochem. 1994 Nov;42(11):1417-25 [7523489.001]
  • [Cites] Hum Pathol. 1998 May;29(5):498-504 [9596274.001]
  • [Cites] Nat Med. 1998 Jul;4(7):844-7 [9662379.001]
  • [Cites] J Clin Oncol. 2005 Jan 1;23(1):49-57 [15545668.001]
  • [Cites] Diagn Cytopathol. 2005 Oct;33(4):228-32 [16138375.001]
  • [Cites] Clin Cancer Res. 2005 Nov 15;11(22):7986-94 [16299227.001]
  • [Cites] Cell Oncol. 2005;27(5-6):319-26 [16373964.001]
  • [Cites] Lab Invest. 2006 Apr;86(4):398-408 [16446704.001]
  • [Cites] J Pathol. 2006 Sep;210(1):49-58 [16823893.001]
  • [Cites] Cancer Res. 2006 Dec 1;66(23):11148-55 [17145858.001]
  • [Cites] Am J Surg Pathol. 2000 Jan;24(1):4-18 [10632483.001]
  • (PMID = 17965221.001).
  • [ISSN] 1472-4146
  • [Journal-full-title] Journal of clinical pathology
  • [ISO-abbreviation] J. Clin. Pathol.
  • [Language] eng
  • [Grant] United Kingdom / Cancer Research UK / / 11886
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Biomarkers, Tumor; 0 / DNA, Neoplasm; EC 2.7.10.1 / Proto-Oncogene Proteins c-kit
  • [Other-IDs] NLM/ PMC2095465
  •  go-up   go-down


Advertisement
4. Graham C, Tucker C, Creech J, Favours E, Billups CA, Liu T, Fouladi M, Freeman BB 3rd, Stewart CF, Houghton PJ: Evaluation of the antitumor efficacy, pharmacokinetics, and pharmacodynamics of the histone deacetylase inhibitor depsipeptide in childhood cancer models in vivo. Clin Cancer Res; 2006 Jan 1;12(1):223-34
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Several structurally diverse HDAC inhibitors have been developed as cancer therapeutic agents and in vitro have been shown to cause differentiation, cell cycle arrest, or apoptosis.
  • Here, we have evaluated depsipeptide, a natural tetrapeptide HDAC inhibitor, against a panel of pediatric solid tumor models in vivo and evaluated pharmacokinetic and pharmacodynamic variables with tumor sensitivity.
  • EXPERIMENTAL DESIGN: Depsipeptide was administered at the maximum tolerated dose (4.4 mg/kg administered every 7 days x 3 i.v. repeated q21d for a total of two cycles) to scid mice bearing 39 independently derived childhood tumors (9 brain tumors, 11 kidney cancers, 9 rhabdomyosarcomas, 3 neuroblastomas, and 7 osteosarcomas).
  • RESULTS: Of 39 tumors evaluated, three showed objective tumor regressions [two brain tumors (primitive neuroectodermal tumor and atypical teratoid malignant rhabdoid tumor) and one Wilms' tumor].
  • Depsipeptide inhibited growth of many tumor lines but achieved stable disease (<25% increase in volume during treatment cycle 1) in only two tumor models (anaplastic astrocytoma, two rhabdomyosarcomas, and a Wilms' tumor).
  • In two sensitive tumor lines, IRS56 and BT27 (both wild-type p53) p53 increased in treated tumors being maximal at 8 hours and associated with induction of p21(cip1), whereas p53 was stable in tumors with mutant p53.
  • CONCLUSIONS: Our results show that depsipeptide inhibits its target in vivo causing increased histone acetylation; however, this does not correlate with drug sensitivity.
  • The relatively low objective response rate [3 of 39 (8%) tumor lines showing greater than or equal to partial response and 4 (10%) stable disease] administered at dose levels that give clinically relevant drug exposures suggests that as a single agent depsipeptide may have limited clinical utility against pediatric solid tumors in a first-line setting.
  • [MeSH-major] Depsipeptides / pharmacokinetics. Depsipeptides / therapeutic use. Enzyme Inhibitors / pharmacokinetics. Enzyme Inhibitors / therapeutic use. Histone Deacetylases / drug effects. Neoplasms, Experimental / drug therapy
  • [MeSH-minor] Acetylation / drug effects. Animals. Blotting, Western. Cell Line, Tumor. Child. Disease Models, Animal. Female. Histones / drug effects. Humans. Mice. Mice, SCID. Neoplasm Transplantation. Reverse Transcriptase Polymerase Chain Reaction. Tumor Suppressor Protein p53 / drug effects

  • Genetic Alliance. consumer health - Childhood Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16397046.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA21765; United States / NCI NIH HHS / CA / CA23099; United States / NCI NIH HHS / CA / CA96696
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Depsipeptides; 0 / Enzyme Inhibitors; 0 / Histones; 0 / Tumor Suppressor Protein p53; EC 3.5.1.98 / Histone Deacetylases
  •  go-up   go-down


5. Chang CJ, Yeh ML, Chen CC: Rhabdoid tumor of the kidney with spontaneous rupture: case report and review of literature. Pediatr Surg Int; 2008 Apr;24(4):451-3
MedlinePlus Health Information. consumer health - Kidney Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Rhabdoid tumor of the kidney with spontaneous rupture: case report and review of literature.
  • Spontaneous rupture of the kidney is uncommon; here we report a case of spontaneous rupture of the kidney due to a rhabdoid tumor.
  • An 11-year-old boy presented with left flank pain and hematuria, was admitted to a hospital where he was found to have an abnormality of the left kidney on computed tomography (CT) scan.
  • He was referred to our department for further evaluation and treatment on the next day.
  • Spontaneous rupture of left renal tumor was suspected by a drop in hemoglobin level, hemoglobin decreased from 9.2 to 7.6 mg/dl within 72 h.
  • Urgent trans-abdominal exploration of the left kidney was performed.
  • During the operation, rupture of left renal tumor with massive bleeding was noted.
  • The surgical specimen contained a large peri-renal hemorrhage and tumor rupture into peri-pelvic soft tissue.
  • Histopathological diagnosis was rhabdoid tumor consisting of round nuclei, prominent nucleoli and eosinophic cytoplasm.
  • Two courses of adjuvant chemotherapy with actinomycin D, vincristine and epirubicin and radiotherapy (1,200 cGY) were performed post-operatively.
  • The patient died 5 months after operation due to metastasis of the tumor to the lung and intra-abdominal organs.
  • [MeSH-major] Kidney Neoplasms / complications. Rhabdoid Tumor / complications
  • [MeSH-minor] Child. Fatal Outcome. Hemorrhage / etiology. Humans. Kidney Diseases / etiology. Male. Rupture, Spontaneous / complications

  • Genetic Alliance. consumer health - Rhabdoid tumor.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Hum Pathol. 1981 Jul;12(7):646-57 [7275104.001]
  • [Cites] AJR Am J Roentgenol. 1997 Feb;168(2):447-51 [9016225.001]
  • [Cites] Cancer. 1984 Nov 15;54(10):2137-46 [6091860.001]
  • [Cites] Cancer. 1989 Jul 15;64(2):349-60 [2544249.001]
  • [Cites] Am J Surg Pathol. 1989 Jun;13(6):439-58 [2543225.001]
  • [Cites] J Pediatr Hematol Oncol. 2001 Feb;23(2):105-8 [11216700.001]
  • [Cites] Cancer. 1978 May;41(5):1937-48 [206343.001]
  • [Cites] J Clin Oncol. 2005 Oct 20;23(30):7641-5 [16234525.001]
  • [Cites] J Pediatr Hematol Oncol. 1999 Jan-Feb;21(1):53-7 [10029814.001]
  • (PMID = 17492291.001).
  • [ISSN] 0179-0358
  • [Journal-full-title] Pediatric surgery international
  • [ISO-abbreviation] Pediatr. Surg. Int.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Germany
  • [Number-of-references] 10
  •  go-up   go-down


6. Alavi S, Rashidi A, Khatami AR, Arzanian MT: Rhabdoid tumor of the kidney presenting with hemiplegia: report of a case. Pediatr Hematol Oncol; 2007 Mar;24(2):123-8
MedlinePlus Health Information. consumer health - Kidney Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Rhabdoid tumor of the kidney presenting with hemiplegia: report of a case.
  • Rhabdoid tumor of the kidney (RTK) is a rare and highly malignant neoplasm of infancy, with a strong tendency for early metastasis to distant regions.
  • RTK is unique in its significant association with primary or metastatic brain tumors.
  • The authors report the first case of RTK presenting initially with hemiplegia.
  • The patient was found thereafter to have RTK concurrent with pulmonary metastases, a brain tumor, and a cerebral ischemic lesion.
  • Intensive chemotherapy consisting of carboplatin and etoposide alternating with cyclophosphamide was unsuccessful and the patient died 5 months later because of severe respiratory distress resulting from widespread pulmonary metastases.
  • [MeSH-major] Cerebellar Neoplasms / pathology. Hemiplegia / complications. Kidney Neoplasms / pathology. Neoplasms, Multiple Primary / pathology. Rhabdoid Tumor / pathology
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Brain Ischemia / drug therapy. Brain Ischemia / pathology. Fatal Outcome. Female. Humans. Infant. Lung Neoplasms / drug therapy. Lung Neoplasms / secondary. Magnetic Resonance Imaging. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Hemiplegia.
  • Genetic Alliance. consumer health - Rhabdoid tumor.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17454778.001).
  • [ISSN] 1521-0669
  • [Journal-full-title] Pediatric hematology and oncology
  • [ISO-abbreviation] Pediatr Hematol Oncol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  •  go-up   go-down


7. Koga Y, Matsuzaki A, Suminoe A, Hatano M, Saito Y, Kinoshita Y, Tajiri T, Taguchi T, Kohashi K, Oda Y, Tsuneyoshi M, Hara T: Long-term survival after autologous peripheral blood stem cell transplantation in two patients with malignant rhabdoid tumor of the kidney. Pediatr Blood Cancer; 2009 Jul;52(7):888-90
Hazardous Substances Data Bank. VINCRISTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Long-term survival after autologous peripheral blood stem cell transplantation in two patients with malignant rhabdoid tumor of the kidney.
  • A 5-month-old male with stage II malignant rhabdoid tumor of the kidney (MRTK) and a 24-month-old male with stage III MRTK were treated with surgical resection of tumors and chemotherapy of alternating ICE (ifosfamide, carboplatin, and etoposide) and VDC (vincristine, doxorubicin, and cyclophosphamide), followed by high-dose chemotherapy using etoposide, carboplatin, and melphalan with autologous hematopoietic stem cell transplantation (SCT).
  • Two patients have been alive without any evidence of disease for 30 and 37 months after diagnosis, respectively, and require no medication.
  • Consolidation with SCT should be further studies for selected patients with high-risk MRTK.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Hematopoietic Stem Cell Transplantation. Kidney Neoplasms / mortality. Kidney Neoplasms / therapy. Rhabdoid Tumor / mortality. Rhabdoid Tumor / therapy
  • [MeSH-minor] Carboplatin / administration & dosage. Combined Modality Therapy. Cyclophosphamide / administration & dosage. Doxorubicin / administration & dosage. Etoposide / administration & dosage. Humans. Ifosfamide / administration & dosage. Infant. Male. Melphalan / administration & dosage. Prognosis. Survival Rate. Tomography, X-Ray Computed. Transplantation, Autologous. Treatment Outcome. Vincristine / administration & dosage

  • Genetic Alliance. consumer health - Rhabdoid tumor.
  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. MELPHALAN .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. IFOSFAMIDE .
  • Hazardous Substances Data Bank. CARBOPLATIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2009 Wiley-Liss, Inc.
  • (PMID = 19260106.001).
  • [ISSN] 1545-5017
  • [Journal-full-title] Pediatric blood & cancer
  • [ISO-abbreviation] Pediatr Blood Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 5J49Q6B70F / Vincristine; 6PLQ3CP4P3 / Etoposide; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; BG3F62OND5 / Carboplatin; Q41OR9510P / Melphalan; UM20QQM95Y / Ifosfamide
  •  go-up   go-down


8. Sahdev I, James-Herry A, Scimeca P, Parker R: Concordant rhabdoid tumor of the kidney in a set of identical twins with discordant outcomes. J Pediatr Hematol Oncol; 2003 Jun;25(6):491-4
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Concordant rhabdoid tumor of the kidney in a set of identical twins with discordant outcomes.
  • We report identical twin boys who each had stage IV rhabdoid tumor of the left kidney at the age of 5 months and 2 years, respectively.
  • The 5-month-old boy, despite receiving chemotherapy, died of progressive disease at the age of 12 months.
  • Following resection of the tumor, his twin brother was treated with 6 cycles of combination chemotherapy consisting of cisplatinum, doxorubicin, vincristine, cyclophosphamide, and actinomycin-D alternating with ifosfamide and etoposide.
  • High-dose chemotherapy followed by autologous stem cell transplant may be an effective front-line therapeutic approach for patients with metastatic rhabdoid tumor of the kidney.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Diseases in Twins. Kidney Neoplasms / pathology. Peripheral Blood Stem Cell Transplantation. Rhabdoid Tumor / pathology
  • [MeSH-minor] Child, Preschool. Combined Modality Therapy. Fatal Outcome. Humans. Infant. Male. Transplantation, Autologous. Treatment Outcome. Twins, Monozygotic

  • Genetic Alliance. consumer health - Rhabdoid tumor.
  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12794530.001).
  • [ISSN] 1077-4114
  • [Journal-full-title] Journal of pediatric hematology/oncology
  • [ISO-abbreviation] J. Pediatr. Hematol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 19
  •  go-up   go-down


9. Yamamoto M, Suzuki N, Hatakeyama N, Mizue N, Hori T, Kuroiwa Y, Hareyama M, Oda T, Kudoh T, Nui A, Matsuno T, Hirama T, Yokoyama S, Dome JS, Tsutsumi H: Treatment of stage IV malignant rhabdoid tumor of the kidney (MRTK) with ICE and VDCy: a case report. J Pediatr Hematol Oncol; 2006 May;28(5):286-9
Hazardous Substances Data Bank. VINCRISTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment of stage IV malignant rhabdoid tumor of the kidney (MRTK) with ICE and VDCy: a case report.
  • The prognosis of stage IV malignant rhabdoid tumor of the kidney (MRTK) has been extremely poor.
  • However, a combination of ICE (ifosfamide, carboplatin, and etoposide) and VDCy (vincristine, doxorubicin, and cyclophosphamide) was recently reported to be effective for metastatic MRTK.
  • We describe a 21-month-old girl with stage IV MRTK who was successfully treated with ICE, VDCy, and radiotherapy.
  • She remained well, without recurrence, 24 months after diagnosis.
  • Alternating therapy with ICE and VDCy might become a standard regimen for stage IV MRTK, although further study is required to confirm its effectiveness.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Kidney Neoplasms / drug therapy. Rhabdoid Tumor / drug therapy

  • Genetic Alliance. consumer health - Rhabdoid tumor.
  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. IFOSFAMIDE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16772877.001).
  • [ISSN] 1077-4114
  • [Journal-full-title] Journal of pediatric hematology/oncology
  • [ISO-abbreviation] J. Pediatr. Hematol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 5J49Q6B70F / Vincristine; 6PLQ3CP4P3 / Etoposide; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; Q20Q21Q62J / Cisplatin; UM20QQM95Y / Ifosfamide; ICE protocol 1
  •  go-up   go-down


10. Radhika S, Bakshi A, Rajwanshi A, Nijhawan R, Das A, Kakkar N, Joshi K, Marwaha RK, Rao KL: Cytopathology of uncommon malignant renal neoplasms in the pediatric age group. Diagn Cytopathol; 2005 May;32(5):281-6
MedlinePlus Health Information. consumer health - Kidney Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cytopathology of uncommon malignant renal neoplasms in the pediatric age group.
  • Malignant renal neoplasms are common solid tumors in pediatric oncology practice.
  • These include the common Wilms' tumor/nephroblastoma and the uncommon neoplasms such as clear-cell sarcoma of the kidney (CCSK), rhabdoid tumor, renal-cell carcinoma, and others.
  • The aim of this study was to describe in detail the cytopathological features of the histopathologically proven uncommon pediatric renal tumors.
  • Aspirates from Wilms' tumor, which are mesenchyme predominant, show clusters of spindle cells associated with the matrix material.
  • Renal-cell carcinoma of childhood shows similar cytological features as its adult counterpart.
  • Rhabdoid tumor of the kidney is characterized by a monomorphic population of cells with abundant cytoplasm, eccentric nuclei with prominent nucleoli.
  • Intrarenal yolk sac tumor is a rare neoplasm and shows severely pleomorphic cells on aspiration.
  • Further, non-Wilms' renal malignant neoplasms must be distinguished from the common Wilms' tumor so that appropriate chemotherapy protocols may be instituted in cases where the tumor is in an advanced stage of malignancy.
  • [MeSH-major] Biopsy, Fine-Needle / methods. Carcinoma, Renal Cell / pathology. Endodermal Sinus Tumor / pathology. Kidney Neoplasms / pathology. Rhabdoid Tumor / pathology. Sarcoma, Clear Cell / pathology
  • [MeSH-minor] Adolescent. Cell Nucleus / pathology. Child. Child, Preschool. Diagnosis, Differential. Humans. Infant. Staining and Labeling. Wilms Tumor / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2005 Wiley-Liss, Inc.
  • (PMID = 15830360.001).
  • [ISSN] 8755-1039
  • [Journal-full-title] Diagnostic cytopathology
  • [ISO-abbreviation] Diagn. Cytopathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


11. Soffer SZ, Kim E, Huang J, McCrudden K, Yokoi A, Moore JT, Manley C, O'Toole K, Middlesworth W, Stolar C, Yamashiro DJ, Kandel JJ: Resistance of a VEGF-producing tumor to anti-VEGF antibody: unimpeded growth of human rhabdoid tumor xenografts. J Pediatr Surg; 2002 Mar;37(3):528-32
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Resistance of a VEGF-producing tumor to anti-VEGF antibody: unimpeded growth of human rhabdoid tumor xenografts.
  • BACKGROUND/PURPOSE: Rhabdoid tumor of the kidney (RTK) is a lethal malignancy of childhood for which there currently are no effective therapies.
  • Because vascular endothelial growth factor (VEGF) is nearly ubiquitous in human tumors, the authors hypothesized that a xenograft model of RTK would (1) express VEGF and (2) respond to anti-VEGF intervention.
  • METHODS: A total of 2 x 10(6) cultured RTK cells were implanted intrarenally (G-401) in athymic mice.
  • Apoptosis was assessed by TdT-mediated dUTP nick end labeling (TUNEL) assay, VEGF expression examined by reverse transcription polymerase chain reaction, and tumor weights compared by Kruskal-Wallis analysis.
  • RESULTS: Mean tumor weights were not altered significantly by anti-VEGF (0.78-g, controls v 0.56-g treated tumors; P value, not significant).
  • Grossly, xenografts grew in a novel manner, encasing rather than invading the kidney, and did not metastasize.
  • CONCLUSIONS: Unexpectedly, growth of RTK xenografts was not inhibited by specific anti-VEGF antibody, although these tumors express significant amounts of VEGF.
  • In addition, RTK vasculature, apoptosis, and VEGF expression were not substantially altered by anti-VEGF antibody.
  • These results suggest that tumor-derived VEGF is of highly variable importance in different malignancies.
  • [MeSH-major] Antibodies, Monoclonal / pharmacology. Antineoplastic Agents / pharmacology. Endothelial Growth Factors / immunology. Kidney Neoplasms / drug therapy. Kidney Neoplasms / pathology. Lymphokines / immunology. Rhabdoid Tumor / drug therapy. Rhabdoid Tumor / pathology. Transplantation, Heterologous / pathology
  • [MeSH-minor] Animals. Antigens, CD31 / immunology. Drug Resistance, Neoplasm. Female. Humans. Immunohistochemistry. Lung Neoplasms / drug therapy. Lung Neoplasms / metabolism. Lung Neoplasms / pathology. Mice. Mice, Nude. Paraffin Embedding. Vascular Endothelial Growth Factor A. Vascular Endothelial Growth Factors

  • Genetic Alliance. consumer health - Rhabdoid tumor.
  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2002 by W.B. Saunders Company.
  • (PMID = 11877682.001).
  • [ISSN] 1531-5037
  • [Journal-full-title] Journal of pediatric surgery
  • [ISO-abbreviation] J. Pediatr. Surg.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antigens, CD31; 0 / Antineoplastic Agents; 0 / Endothelial Growth Factors; 0 / Lymphokines; 0 / Vascular Endothelial Growth Factor A; 0 / Vascular Endothelial Growth Factors
  •  go-up   go-down


12. Luo CC, Lin JN, Jaing TH, Yang CP, Hsueh C: Malignant rhabdoid tumour of the kidney occurring simultaneously with a brain tumour: a report of two cases and review of the literature. Eur J Pediatr; 2002 Jun;161(6):340-2
MedlinePlus Health Information. consumer health - Kidney Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Malignant rhabdoid tumour of the kidney occurring simultaneously with a brain tumour: a report of two cases and review of the literature.
  • Malignant rhabdoid tumour of the kidney (MRTK), an uncommon aggressive neoplasm of children, is now recognised as a separate entity from Wilms' tumour with distinct clinical and pathological features.
  • MRTK is unique in its significant association with primary brain tumours or brain metastases.
  • We report two cases, aged 2 and 6 months, of MRTK occurring concurrently with a brain tumour.
  • Both patients expired 2 and 6 months later despite receiving aggressive post-operative chemotherapy and radiotherapy.
  • CONCLUSION: malignant rhabdoid tumour of the kidney is an uncommon neoplasm of early childhood with a poor prognosis.
  • [MeSH-major] Brain Neoplasms / pathology. Kidney Neoplasms / pathology. Neoplasms, Multiple Primary. Rhabdoid Tumor / pathology. Sarcoma, Clear Cell / pathology
  • [MeSH-minor] Humans. Infant. Male. Tomography, X-Ray Computed

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12029454.001).
  • [ISSN] 0340-6199
  • [Journal-full-title] European journal of pediatrics
  • [ISO-abbreviation] Eur. J. Pediatr.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


13. Naraghi S, Khoshyomn S, DeMattia JA, Vane DW: Receptor tyrosine kinase inhibition suppresses growth of pediatric renal tumor cells in vitro. J Pediatr Surg; 2000 Jun;35(6):884-90
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Receptor tyrosine kinase inhibition suppresses growth of pediatric renal tumor cells in vitro.
  • PURPOSE: Children who undergo standard therapy for renal tumors are at an increased risk for treatment sequelae such as congestive heart failure, abnormal trunk development, and secondary malignancies.
  • Recent experimental evidence suggests that growth factor receptors such as epidermal growth factor receptor (EGFR) and platelet-derived growth factor receptor (PDGFR) play an important role in growth and development of pediatric renal tumors especially that of Wilms' tumor.
  • In this study we investigated the effects of genistein, AG1478, and AG1295, from the class of growth factor receptor tyrosine kinase (GFR-TK) inhibitors, on proliferation and colonigenic growth of 2 pediatric renal tumor cell lines.
  • METHODS: The authors studied the effect of genistein (broad-spectrum GFR-TK inhibitor), AG1478 (EGFR-specific GFR-TK inhibitor), and AG1295 (PDGFR-specific GFR-TK inhibitor) on proliferation and colonigenic growth of rhabdoid tumor of the kidney and Wilms' tumor cell lines: G-401 and SK-NEP-1, respectively.
  • Viable cell counts at each concentration were obtained by hemocytometer and trypan blue exclusion, and percent growth inhibition was calculated based on control cultures at the same time-point.
  • As a measure of colonigenic survival, the percent inhibition of colony formation in drug-treated dishes was calculated based on the number of colonies (>50 cells) in control dishes.
  • CONCLUSIONS: This is the first experimental study on the use of GFR-TK inhibitors as a potential treatment for pediatric renal tumors.
  • GFR-TK inhibitors such as genistein occur naturally in soybean foods and have been shown to reach therapeutic levels in blood after consuming a soybean-based diet.
  • Considering the significance of growth factor receptor activity in Wilms' tumor development, inhibition of GFR-TKs should be investigated as effective and potentially nontoxic adjunctive treatment for this childhood tumor.
  • Furthermore, GFR-TK inhibitors may offer an effective alternative to the treatment of commonly fatal rhabdoid tumor of the kidney in children.
  • [MeSH-major] Kidney Neoplasms / drug therapy. Receptor Protein-Tyrosine Kinases / antagonists & inhibitors. Tyrphostins / therapeutic use
  • [MeSH-minor] Adult. Cell Division / drug effects. Drug Screening Assays, Antitumor. Enzyme Inhibitors / therapeutic use. Female. Genistein / therapeutic use. Humans. Infant. Male. Platelet-Derived Growth Factor / antagonists & inhibitors. Protein Tyrosine Phosphatases / antagonists & inhibitors. Quinazolines. Rhabdoid Tumor / drug therapy. Rhabdoid Tumor / pathology. Tumor Cells, Cultured / drug effects. Tumor Cells, Cultured / pathology. Tumor Stem Cell Assay. Wilms Tumor / drug therapy. Wilms Tumor / pathology

  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • Hazardous Substances Data Bank. GENISTEIN .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10873031.001).
  • [ISSN] 0022-3468
  • [Journal-full-title] Journal of pediatric surgery
  • [ISO-abbreviation] J. Pediatr. Surg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] UNITED STATES
  • [Chemical-registry-number] 0 / 6,7-dimethoxy-2-phenylquinoxaline; 0 / Enzyme Inhibitors; 0 / Platelet-Derived Growth Factor; 0 / Quinazolines; 0 / Tyrphostins; 170449-18-0 / tyrphostin AG 1478; DH2M523P0H / Genistein; EC 2.7.10.1 / Receptor Protein-Tyrosine Kinases; EC 3.1.3.48 / Protein Tyrosine Phosphatases
  •  go-up   go-down


14. Takamizawa S, Okamoto S, Bishop W, Wen J, Kimura K, Sandler A: Differential apoptosis gene expression in pediatric tumors of the kidney. J Pediatr Surg; 2000 Feb;35(2):390-5
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Differential apoptosis gene expression in pediatric tumors of the kidney.
  • BACKGROUND/PURPOSE: Apoptosis, or programmed cell death, is essential in maintaining normal homeostasis of tissues.
  • Variations in expression of such factors may account for some variations in tumor behavior.
  • This study evaluates the expression of apoptotic mRNA species in pediatric renal tumors to determine whether a pattern of differential apoptosis gene expression correlates with tumor grade and type.
  • METHODS: Twenty-five frozen tissue specimens were obtained from patients undergoing biopsy or resection of pediatric renal tumors before chemotherapy: Wilms' tumor stage II (WT-II, n = 4); Wilms' tumor stage III/IV (WT-III/IV, n = 4); clear cell sarcoma of the kidney stage III (CCSK, n = 2); rhabdoid tumor of the kidney stage III/IV (RTK, n = 4); and normal kidney (NK, n = 11).
  • WT-II expressed greater amounts of proapoptotic receptor mRNA than CCSK or RTK. (Fas, 17.0+/-2.7% v. 2.5+/-0.5% v. 3.3+/-0.9%; P<.02; DR5, 77.0+/-8.8% v. 13.5+/-0.5% v. 27.0+/-4.8; P<.001; TNF-R, 71.3+/-17.0% v. 21.0+/-4.0% v. 29.0+/-5.0%; P<.07, respectively).
  • Surprisingly, antiapoptotic factors (e.g., bcl-2 and bcl-xl) were not overexpressed in poor prognostic tumors (CCSK, RTK) compared with those with good prognosis (WT).
  • Expression of TRAIL (a ligand for DR4 and DR5) was significantly lower in CCSK and RTK than in normal kidney (9.5+/-1.5% v. 56.1+/-10.1%; P = .01).
  • [MeSH-major] Apoptosis / genetics. Gene Expression. Kidney Neoplasms / pathology
  • [MeSH-minor] Blotting, Western. Child. Genes, bcl-2 / physiology. HLA-DR Antigens / physiology. Humans. Neoplasm Staging. Neoplasms, Germ Cell and Embryonal / genetics. Neoplasms, Germ Cell and Embryonal / pathology. Neoplasms, Germ Cell and Embryonal / physiopathology. RNA, Messenger / isolation & purification. RNA, Messenger / metabolism. Rhabdoid Tumor / genetics. Rhabdoid Tumor / pathology. Rhabdoid Tumor / physiopathology. Tumor Necrosis Factor-alpha / metabolism. Wilms Tumor / genetics. Wilms Tumor / pathology. Wilms Tumor / physiopathology

  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10693703.001).
  • [ISSN] 0022-3468
  • [Journal-full-title] Journal of pediatric surgery
  • [ISO-abbreviation] J. Pediatr. Surg.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] UNITED STATES
  • [Chemical-registry-number] 0 / HLA-DR Antigens; 0 / RNA, Messenger; 0 / Tumor Necrosis Factor-alpha
  •  go-up   go-down


15. Stehr M, Deilmann K, Haas RJ, Dietz HG: Surgical complications in the treatment of Wilms' tumor. Eur J Pediatr Surg; 2005 Dec;15(6):414-9
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Surgical complications in the treatment of Wilms' tumor.
  • We present our data on the treatment of Wilms' Tumor (WT) with an emphasis on both the positive effect and the adverse effect of preoperative chemotherapy with regard to surgical intervention.
  • 57 % received preoperative chemotherapy (ChTx) and 43 % were operated on primarily.
  • In 8 % of the patients with preoperative chemotherapy intraoperative complications occurred with a rupture of the tumor in 1 case.
  • In contrast, there were intraoperative complications in 25 % of the patients with a primary operation with rupture of the tumor in 3 cases.
  • 1 child (1.5 %) was treated with chemotherapy who did not have a Wilms' tumor but a benign nephroma (CMN).
  • 3 cases had a clear cell sarcoma (CCSK) and in one case histology revealed a rhabdoid tumor (MRTK).
  • In one case of CCSK only histology of the metastases disclosed the correct diagnosis.
  • Irrespective of the known adverse effects such as changing tumor histology, which may affect the correct staging, and the remaining risk of an initial inadequate treatment, our data show that the regimen of preoperative chemotherapy as proposed by the SIOP study should not be abandoned.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Intraoperative Complications. Kidney Neoplasms / drug therapy. Kidney Neoplasms / surgery. Nephrectomy. Wilms Tumor / drug therapy. Wilms Tumor / surgery
  • [MeSH-minor] Child, Preschool. Dactinomycin / administration & dosage. Humans. Neoadjuvant Therapy. Neoplasm Staging. Postoperative Complications. Vincristine / administration & dosage

  • Genetic Alliance. consumer health - Wilms' tumor.
  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • MedlinePlus Health Information. consumer health - Wilms Tumor.
  • Hazardous Substances Data Bank. DACTINOMYCIN .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16418959.001).
  • [ISSN] 0939-7248
  • [Journal-full-title] European journal of pediatric surgery : official journal of Austrian Association of Pediatric Surgery ... [et al] = Zeitschrift für Kinderchirurgie
  • [ISO-abbreviation] Eur J Pediatr Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 1CC1JFE158 / Dactinomycin; 5J49Q6B70F / Vincristine
  •  go-up   go-down


16. Takamizawa S, Scott D, Wen J, Grundy P, Bishop W, Kimura K, Sandler A: The survivin:fas ratio in pediatric renal tumors. J Pediatr Surg; 2001 Jan;36(1):37-42
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The survivin:fas ratio in pediatric renal tumors.
  • Fas is a pro-apoptotic receptor that induces cell death when bound by its ligand and is expressed at greater levels in pediatric renal tumors of good prognosis.
  • This study evaluates the expression of survivin, as well as the prognostic value of the survivin:fas ratio in various types and stages of pediatric renal tumors.
  • METHODS: Multiple apoptosis mRNA species were quantified by Rnase protection assay (RPA) in 32 pediatric renal tumors and adjacent normal kidney specimens before chemotherapy: Wilms' tumor (WT), n = 9; clear cell sarcoma (CCS), n = 4; rhabdoid tumor of the kidney (RTK), n = 5; mesoblastic nephroma (MN), n = 3 and normal kidney, n = 11.
  • RESULTS: Pediatric renal tumors express greater levels of both pro- and antiapoptotic factors than normal kidney.
  • Survivin and fas appeared to be expressed differentially in the tumor specimens sampled.
  • The mean survivin:fas ratio was significantly greater in the 10 tumors that went on to recur after treatment (4 RTK, 3 CCS, 3 WT), than in tumors not recurring (2.16+/-1.4 v 1.0+/-1.07; P =.01, Kruskal-Wallis test).
  • The positive predictive value of tumor recurrence was 85.7% (CI: 42.1%, 99.6%) and the negative predictive value was 71.4% (CI: 41.9%, 91.6%) when a cutoff ratio of 1.6 was considered.
  • CONCLUSIONS: The survivin:fas mRNA ratio is of prognostic value in its ability to predict recurrent disease in children undergoing treatment for pediatric renal tumors.
  • In this series, a ratio of greater than 1.6 predicted recurrent disease with a high probability irrespective of clinical stage or pathologic type.
  • Determining the survivin:fas ratio may guide treatment, follow-up and counseling of patients with pediatric renal tumors.
  • [MeSH-major] Antigens, CD95 / metabolism. Kidney Neoplasms / metabolism. Microtubule-Associated Proteins. Proteins / metabolism. RNA, Messenger / metabolism
  • [MeSH-minor] Apoptosis. Blotting, Western. Child. Humans. Immunoenzyme Techniques. Inhibitor of Apoptosis Proteins. Neoplasm Proteins. Neoplasm Recurrence, Local / diagnosis. Predictive Value of Tests. Prognosis. Statistics, Nonparametric

  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11150435.001).
  • [ISSN] 0022-3468
  • [Journal-full-title] Journal of pediatric surgery
  • [ISO-abbreviation] J. Pediatr. Surg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] UNITED STATES
  • [Chemical-registry-number] 0 / Antigens, CD95; 0 / BIRC5 protein, human; 0 / Inhibitor of Apoptosis Proteins; 0 / Microtubule-Associated Proteins; 0 / Neoplasm Proteins; 0 / Proteins; 0 / RNA, Messenger
  •  go-up   go-down


17. Powis M: Neonatal renal tumours. Early Hum Dev; 2010 Oct;86(10):607-12
MedlinePlus Health Information. consumer health - Wilms Tumor.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Neonatal renal tumours.
  • Neonatal renal tumours are rare, with only 7% of all neonatal tumours arising from the kidney.
  • Mesoblastic nephroma is the most common tumour to be found at this age, but Wilms' tumour and other malignant and benign tumours occur.
  • Given the low malignant potential of these tumours, treatment is by radical nephroureterctomy, except in cases with bilateral disease or syndromic patients with a high incidence of metachronous tumours.
  • Chemotherapy is rarely indicated.
  • Survival is generally excellent for all tumour types in this age group, the exception being malignant rhabdoid tumour of the kidney which may have metastases at presentation.
  • [MeSH-major] Kidney Neoplasms / diagnosis. Nephroma, Mesoblastic / diagnosis. Wilms Tumor / diagnosis
  • [MeSH-minor] Anatomy, Cross-Sectional. Diagnosis, Differential. Genetic Predisposition to Disease. Humans. Imaging, Three-Dimensional. Infant, Newborn. Neuroblastoma / diagnosis. Practice Guidelines as Topic. Risk Factors

  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 Elsevier Ireland Ltd. All rights reserved.
  • (PMID = 20888153.001).
  • [ISSN] 1872-6232
  • [Journal-full-title] Early human development
  • [ISO-abbreviation] Early Hum. Dev.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Ireland
  •  go-up   go-down


18. Reinhard H, Semler O, Bürger D, Bode U, Flentje M, Göbel U, Gutjahr P, Leuschner I, Maass E, Niggli F, Scheel-Walter HG, Stöckle M, Thüroff JW, Tröger J, Weirich A, von Schweinitz D, Zoubek A, Graf N: Results of the SIOP 93-01/GPOH trial and study for the treatment of patients with unilateral nonmetastatic Wilms Tumor. Klin Padiatr; 2004 May-Jun;216(3):132-40
ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Results of the SIOP 93-01/GPOH trial and study for the treatment of patients with unilateral nonmetastatic Wilms Tumor.
  • BACKGROUND: The treatment of Wilms Tumor is integrated into clinical trials since the 1970's.
  • In contrast to the National Wilms Tumor Study Group (NWTSG) the SIOP trials and studies largely focus on the issue of preoperative therapy to facilitate surgery of a shrunken tumor and to treat metastasis as early as possible.
  • PATIENTS AND METHODS: In the SIOP 93-01/GPOH trial and study 1 020 patients with a newly diagnosed renal tumor were registered.
  • 847 of them had a histological proven Wilms Tumor, of whom 637 were unilateral localized, and 173 tumors had an other histology [40 congenital mesoblastic nephroma (CMN), 51 clear cell sarcoma (CCSK), 24 rhabdoid tumor (RTK) and 58 other tumors].
  • Preoperative chemotherapy in benign tumors was given to 1.3 % of the patients.
  • The main objective of the trial was the randomized question, if the postoperative two drug chemotherapy for stage I in intermediate risk or anaplasia can be reduced from conventional 3 courses to an experimental 1 course without loss of efficacy.
  • RESULTS: 519 patients with unilateral nonmetastatic Wilms did receive preoperative chemotherapy.
  • In 17 (3 %) patients the tumor stage remained unclear.
  • Tumor volume was measured in 487 patients before and in 402 after preoperative chemotherapy.
  • The median tumor volume did shrink from 353 to 126 ml.
  • The event free survival (EFS) after 5 years was 91 % for all patients with unilateral Wilms tumor without distant metastasis.
  • Randomisation was done in 43.7 % for stage I patients and there was no difference in EFS for both treatment arms (90 versus 91 %).
  • The tumor volume after chemotherapy is a prognostic factor for intermediate risk tumors with the exception of epithelial and stromal predominant tumors.
  • These two subtypes often present as large tumors, they do not shrink during preoperative chemotherapy but they still have an excellent prognosis.
  • On the other hand the prognosis of patients with blastemal predominant subtype after preoperative chemotherapy is worse than in any other patient group of intermediate risk tumors.
  • There are less blastemal predominant tumors compared to primary surgery, but they are chemotherapeutic resistant selected by the preoperative chemotherapy.
  • CONCLUSION: Patients with unilateral Wilms tumor without metastasis have an excellent prognosis.
  • The post-operative chemotherapy in stage I can be reduced to 4 weeks without worsening treatment outcome.
  • The reduction of the tumor volume could be identified as a helpful marker for stratification of post-operative treatment.
  • Post-chemotherapy blastemal predominant subtype of Wilms tumor has to be classified as high risk tumor.
  • Focal anaplasia has a better prognosis than diffuse anaplasia and will be classified as intermediate risk tumor.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Kidney Neoplasms / drug therapy. Neoadjuvant Therapy. Wilms Tumor / drug therapy
  • [MeSH-minor] Adolescent. Chemotherapy, Adjuvant. Child. Child, Preschool. Combined Modality Therapy. Disease-Free Survival. Female. Follow-Up Studies. Humans. Infant. Male. Neoplasm Staging. Nephrectomy. Nephroma, Mesoblastic / drug therapy. Nephroma, Mesoblastic / mortality. Nephroma, Mesoblastic / pathology. Nephroma, Mesoblastic / surgery. Prognosis. Rhabdoid Tumor / drug therapy. Rhabdoid Tumor / mortality. Rhabdoid Tumor / pathology. Rhabdoid Tumor / surgery. Sarcoma, Clear Cell / drug therapy. Sarcoma, Clear Cell / mortality. Sarcoma, Clear Cell / pathology. Sarcoma, Clear Cell / surgery

  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • MedlinePlus Health Information. consumer health - Wilms Tumor.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15175957.001).
  • [ISSN] 0300-8630
  • [Journal-full-title] Klinische Pädiatrie
  • [ISO-abbreviation] Klin Padiatr
  • [Language] eng
  • [Publication-type] Clinical Trial; Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  •  go-up   go-down


19. Gottlieb C, Nijhawan N, Chorneyko K, O'Grady KF, Harvey JT: Congenital orbital and disseminated extrarenal malignant rhabdoid tumor. Ophthal Plast Reconstr Surg; 2005 Jan;21(1):76-9
MedlinePlus Health Information. consumer health - Premature Babies.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Congenital orbital and disseminated extrarenal malignant rhabdoid tumor.
  • A diagnosis of malignant rhabdoid tumor was made.
  • Malignant rhabdoid tumors can present as local or disseminated neoplastic disease involving the orbit and should be considered in the differential diagnosis of rapidly progressing orbital lesions presenting in early infancy.
  • We review the current classification of rhabdoid tumors and the previous literature on orbital rhabdoid tumors.
  • [MeSH-major] Infant, Premature, Diseases. Kidney Neoplasms / congenital. Orbital Neoplasms / congenital. Rhabdoid Tumor / congenital
  • [MeSH-minor] Abdominal Neoplasms / congenital. Abdominal Neoplasms / diagnosis. Abdominal Neoplasms / drug therapy. Antigens, Neoplasm / analysis. Biopsy. Diagnosis, Differential. Fatal Outcome. Head and Neck Neoplasms / congenital. Head and Neck Neoplasms / diagnosis. Head and Neck Neoplasms / drug therapy. Humans. Immunohistochemistry. Infant, Newborn. Infant, Premature. Male. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Rhabdoid tumor.
  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15677960.001).
  • [ISSN] 0740-9303
  • [Journal-full-title] Ophthalmic plastic and reconstructive surgery
  • [ISO-abbreviation] Ophthal Plast Reconstr Surg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, Neoplasm
  •  go-up   go-down


20. Argani P, Beckwith JB: Metanephric stromal tumor: report of 31 cases of a distinctive pediatric renal neoplasm. Am J Surg Pathol; 2000 Jul;24(7):917-26
MedlinePlus Health Information. consumer health - Kidney Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Metanephric stromal tumor: report of 31 cases of a distinctive pediatric renal neoplasm.
  • We report 31 cases of a novel pediatric renal neoplasm, metanephric stromal tumor (MST).
  • Gross examination typically revealed a fibrous lesion centered in the renal medulla containing smooth-walled cysts (mean tumor size, 5.5 cm).
  • MST is histologically identical to the stromal component of metanephric adenofibroma (MAF, previously termed nephrogenic adenofibroma) and is an unencapsulated spindle cell lesion that entraps native kidney.
  • Characteristic histologic features of MST include alternating cellularity that imparts a nodular low-power appearance, onion-skin cuffing around entrapped renal tubules, heterologous differentiation (glia or cartilage), and vascular alterations (angiodysplasia of entrapped arterioles, juxtaglomerular cell hyperplasia in entrapped glomeruli).
  • Recognition of this entity can spare a child potentially toxic adjuvant chemotherapy that might be used for lesions in its differential diagnosis, specifically clear cell sarcoma of the kidney.
  • [MeSH-major] Kidney Neoplasms / pathology. Neoplasms, Germ Cell and Embryonal / pathology. Nephroma, Mesoblastic / pathology. Rhabdoid Tumor / pathology
  • [MeSH-minor] Biomarkers, Tumor / analysis. Child. Child, Preschool. Female. Follow-Up Studies. Humans. Immunoenzyme Techniques. Infant. Infant, Newborn. Male. Stromal Cells / chemistry. Stromal Cells / pathology. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10895814.001).
  • [ISSN] 0147-5185
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA-42386
  • [Publication-type] Journal Article; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] UNITED STATES
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


21. Anatol T, Mohammed W, Nunez J: A childhood malignant rhabdoid tumour of the kidney. West Indian Med J; 2002 Sep;51(3):191-3
MedlinePlus Health Information. consumer health - Kidney Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A childhood malignant rhabdoid tumour of the kidney.
  • A case report is presented of a malignant rhabdoid tumour occurring in the kidney of a 23-month-old boy.
  • Important differences between this and the conventional Wilms' tumour include the histological demonstration of sheets or cords of large cells resembling myoblasts, a tendency to frequent clinical relapse, and a high mortality rate despite multimodal therapy.
  • In this child, an encouraging initial response to pre-operative chemotherapy, followed by surgical excision and postoperative triple chemotherapy, was not sustained.
  • Recurrence of pulmonary metastases did not respond to further chemotherapy and whole lung irradiation.
  • [MeSH-major] Kidney Neoplasms / diagnosis. Rhabdoid Tumor / diagnosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12501552.001).
  • [ISSN] 0043-3144
  • [Journal-full-title] The West Indian medical journal
  • [ISO-abbreviation] West Indian Med J
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Jamaica
  •  go-up   go-down


22. Salamanca J, Nevado M, Martínez-González MA, Pérez-Espejo G, Pinedo F: Undifferentiated carcinoma of the jejunum with extensive rhabdoid features. Case report and review of the literature. APMIS; 2008 Oct;116(10):941-6
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Undifferentiated carcinoma of the jejunum with extensive rhabdoid features. Case report and review of the literature.
  • Malignant rhabdoid tumor, first described in the kidney of young infants, is a rare and highly aggressive neoplasm of controversial histogenesis that has been reported at many other sites, including the gastrointestinal tract.
  • However, malignant rhabdoid tumor of the small intestine is very rare, with only seven cases published to date.
  • Microscopically, the tumor was characterized by neoplastic cells with vesicular nuclei, large nucleoli and abundant eccentric cytoplasm with hyaline globular intracytoplasmic inclusions.
  • Immunohistochemically, the neoplasm coexpressed vimentin and epithelial antigens (AE1/AE3, Cam 5.2, CK34betaE12, CK19 and EMA), most of them showing a peculiar immunostaining pattern in relation to the globular inclusions.
  • The patient received postoperative chemotherapy but died 9 months after surgery.
  • In summary, we report the exceptional case of an undifferentiated carcinoma of the jejunum with rhabdoid phenotype.
  • As with tumors at other sites, recognition of rhabdoid morphology in small intestine neoplasms is of significance because the prognosis is extremely poor.
  • [MeSH-major] Carcinoma / pathology. Jejunal Neoplasms / pathology. Liver Neoplasms / secondary. Rhabdoid Tumor / pathology
  • [MeSH-minor] Aged. Anion Exchange Protein 1, Erythrocyte / analysis. Anion Exchange Protein 1, Erythrocyte / metabolism. Biomarkers / analysis. Biomarkers / metabolism. Biopsy. Cell Nucleolus / pathology. Fatal Outcome. Humans. Hyalin / metabolism. Immunohistochemistry. Inclusion Bodies / metabolism. Inclusion Bodies / pathology. Jejunum / metabolism. Jejunum / pathology. Keratins / analysis. Keratins / metabolism. Liver / pathology. Male. Neoplasm Proteins / analysis. Neoplasm Proteins / metabolism. Vimentin / analysis. Vimentin / metabolism

  • MedlinePlus Health Information. consumer health - Intestinal Cancer.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19132990.001).
  • [ISSN] 1600-0463
  • [Journal-full-title] APMIS : acta pathologica, microbiologica, et immunologica Scandinavica
  • [ISO-abbreviation] APMIS
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / Anion Exchange Protein 1, Erythrocyte; 0 / Biomarkers; 0 / CAM 5.2 antigen; 0 / CK-34 beta E12; 0 / Neoplasm Proteins; 0 / Vimentin; 68238-35-7 / Keratins
  • [Number-of-references] 8
  •  go-up   go-down


23. Shet T, Viswanathan S: The cytological diagnosis of paediatric renal tumours. J Clin Pathol; 2009 Nov;62(11):961-9
MedlinePlus Health Information. consumer health - Wilms Tumor.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The cytological diagnosis of paediatric renal tumours.
  • Fine needle aspiration cytology (FNAC) is used for preoperative diagnosis of paediatric renal tumours, especially in centres where preoperative chemotherapy is advocated in Wilms' tumour.
  • This review focuses on salient cytological features in specific paediatric renal tumours, the approach to resolving a differential diagnosis and the role of ancillary methods in diagnosis of paediatric renal tumours.
  • Crucial differential diagnoses include distinguishing: Wilms' tumour from benign tumours in the kidney like multicystic nephroma or congenital mesoblastic nephroma; aggressive non-Wilms' tumours of kidney like rhabdoid tumour of kidney; and Wilms' tumour from other paediatric round cell sarcomas like neuroblastoma, non-Hodgkin lymphoma etc.
  • An approach based on classifying smears according to their cellular patterns as triphasic, round cell, spindle cell or epithelioid cell type assists in classifying paediatric renal tumours on cytology.
  • Immunocytochemistry for WT1, cytokeratin, synaptophysin, leucocyte common antigen and MIC2 will aid in evaluating round cell tumours in the renal region, while WT1, bcl2, vimentin and desmin will be useful for spindle cell tumours in that region.
  • A checklist of common tumours in a particular age group, relevant clinical information, awareness of distinctive and overlapping cytological features, and appropriate use of immunocytochemistry with cytogenetics go a long way in ensuring an accurate cytological diagnosis.
  • Used judiciously, FNAC is as effective a tool as a core biopsy for preoperative diagnosis of paediatric renal tumours, and with experience a 92% accuracy rate can be achieved.
  • [MeSH-major] Kidney Neoplasms / pathology. Wilms Tumor / pathology
  • [MeSH-minor] Adolescent. Age Distribution. Biopsy, Fine-Needle / methods. Carcinoma, Renal Cell / pathology. Child. Child, Preschool. Diagnosis, Differential. Humans. Infant. Infant, Newborn. Nephroma, Mesoblastic / pathology. Rhabdoid Tumor / pathology. Sarcoma, Clear Cell / pathology. Sarcoma, Ewing / pathology. Young Adult

  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19700411.001).
  • [ISSN] 1472-4146
  • [Journal-full-title] Journal of clinical pathology
  • [ISO-abbreviation] J. Clin. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 36
  •  go-up   go-down


24. Jun SY, Choi J, Kang GH, Park SH, Ayala AG, Ro JY: Synovial sarcoma of the kidney with rhabdoid features: report of three cases. Am J Surg Pathol; 2004 May;28(5):634-7
MedlinePlus Health Information. consumer health - Kidney Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Synovial sarcoma of the kidney with rhabdoid features: report of three cases.
  • We report 3 cases of synovial sarcoma with rhabdoid features, initially diagnosed as adult rhabdoid tumors.
  • Two women (case nos.
  • Sonography and computed tomography revealed solid, cystic masses in the right kidneys that ranged in size from 8.5 to 20.0 cm.
  • One patient died of disease, and the other two patients were alive and disease-free after chemotherapy and radiotherapy.
  • Microscopic examination revealed that the tumors were composed mostly of rhabdoid cells with eccentrically located nuclei, prominent nucleoli, and eosinophilic cytoplasm.
  • We also found areas of fasciculated spindle cells, sharply separated from or irregularly admixed with areas of rhabdoid cells.
  • There was tumor necrosis, but no epithelial areas were seen.
  • The tumor cells were positive for CD99 and bcl-2 in all cases and for CD56 in two cases and negative for CD34 and smooth muscle actin in all cases.
  • To verify the possibility of synovial sarcoma with rhabdoid features, reverse transcriptase polymerase chain reaction using RNA extracted from frozen tissue in case no. 1 and formalin-fixed, paraffin-embedded tissue in case nos.
  • These cases indicate that synovial sarcoma of the kidney should be considered in the differential diagnosis of mesenchymal kidney tumors with prominent rhabdoid features.
  • A subset of adult rhabdoid tumors may be a rhabdoid variant of synovial sarcoma, and molecular studies to detect SYT-SSX fusion transcripts are recommended for an accurate diagnosis.
  • [MeSH-major] Kidney Neoplasms / pathology. Rhabdoid Tumor / pathology. Sarcoma, Synovial / pathology
  • [MeSH-minor] Adult. Biomarkers, Tumor / analysis. Cell Nucleus / ultrastructure. Disease-Free Survival. Fatal Outcome. Female. Humans. Male. Oncogene Proteins, Fusion / analysis. RNA, Neoplasm / analysis. Reverse Transcriptase Polymerase Chain Reaction

  • Genetic Alliance. consumer health - Synovial sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15105652.001).
  • [ISSN] 0147-5185
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Oncogene Proteins, Fusion; 0 / RNA, Neoplasm; 0 / SYT-SSX fusion protein
  •  go-up   go-down


25. Schenk JP, Engelmann D, Zieger B, Semler O, Wühl E, Furtwängler R, Graf N, Tröger J: [Radiologic differentiation of rhabdoid tumor from Wilms' tumor and mesoblastic nephroma]. Urologe A; 2005 Feb;44(2):155-61
MedlinePlus Health Information. consumer health - Wilms Tumor.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Radiologic differentiation of rhabdoid tumor from Wilms' tumor and mesoblastic nephroma].
  • [Transliterated title] Bildgebende Differenzierung des Rhabdoidtumors vom Nephroblastom und mesoblastischen Nephrom.
  • Differentiation between rhabdoid tumor (RT) and mesoblastic nephroma (MN) and Wilms' tumor (WT) by imaging studies in babies and young children before histological confirmation is useful to start optimal treatment early.
  • Typical radiologic criteria (crescent-shaped subcapsular liquid areas, tumor lobules, blurred tumor borders, metastasis in the lung, and regional lymph nodes) are described.
  • The score value distribution was analyzed between the tumor entities and by two investigators.RT had significantly higher score values than the MN and WT.
  • Only if more signs are observed together in one case can a RT be presumed, which may indicate an early biopsy before chemotherapy.
  • [MeSH-major] Diagnostic Imaging. Kidney Neoplasms / diagnosis. Nephroma, Mesoblastic / diagnosis. Rhabdoid Tumor / diagnosis. Wilms Tumor / diagnosis
  • [MeSH-minor] Child, Preschool. Diagnosis, Differential. Female. Humans. Infant. Kidney / pathology. Lung Neoplasms / diagnosis. Lung Neoplasms / pathology. Lung Neoplasms / secondary. Lymph Nodes / pathology. Lymphatic Metastasis / diagnosis. Lymphatic Metastasis / pathology. Male. Neoplasm Staging. Observer Variation. Sensitivity and Specificity


26. Tröbs RB, Hänsel M, Friedrich T, Bennek J: A 23-year experience with malignant renal tumors in infancy and childhood. Eur J Pediatr Surg; 2001 Apr;11(2):92-8
MedlinePlus Health Information. consumer health - Wilms Tumor.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A 23-year experience with malignant renal tumors in infancy and childhood.
  • A retrospective analysis of 77 children treated between 1974 and 1996 was undertaken to evaluate morbidity and the evolution of therapy.
  • A Wilms' tumor (WT) was present in 73 children.
  • High-risk WT were diagnosed in 12 of 63 patients (19%) (NB with anaplasia 10, clear cell sarcoma 1, malignant rhabdoid tumor 1).
  • We observed 3 children of school age with renal carcinoma and one patient with an intrarenal neuroblastoma.
  • According to the SIOP/GPOH protocol in 1989, the regimen was switched from primary surgery to preoperative chemotherapy without biopsy in 1989 (11 pats.).
  • In 3 patients preoperative diagnosis by means of imaging failed.
  • During preoperative chemotherapy a venous occlusive disease of the liver occurred in 2 patients.
  • Preoperative chemotherapy led to an impressive tumor shrinkage in the majority of patients.
  • In our experience, reduction of tumor volume due to preoperative chemotherapy facilitates tumor removal by surgery and may prevent tumor spillage and the deleterious effects of radiation in young children.
  • Surgery without delay is necessary if the diagnosis is unclear or the tumor fails to respond to preoperative chemotherapy.
  • [MeSH-major] Kidney Neoplasms / surgery. Wilms Tumor / surgery
  • [MeSH-minor] Antineoplastic Agents / therapeutic use. Chemotherapy, Adjuvant. Child. Child, Preschool. Disease-Free Survival. Female. Humans. Infant. Male. Neoplasm Recurrence, Local / epidemiology. Neoplasm Staging. Prognosis. Retrospective Studies

  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11371043.001).
  • [ISSN] 0939-7248
  • [Journal-full-title] European journal of pediatric surgery : official journal of Austrian Association of Pediatric Surgery ... [et al] = Zeitschrift für Kinderchirurgie
  • [ISO-abbreviation] Eur J Pediatr Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


27. Tang JY, Pan C, Xu M, Xue HL, Chen J, Zhao HL, Gu LL, Wang YP: [Results of Wilms' tumor trial (WT-99) in Shanghai children's medical center]. Zhonghua Er Ke Za Zhi; 2003 Feb;41(2):131-4
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Results of Wilms' tumor trial (WT-99) in Shanghai children's medical center].
  • OBJECTIVE: Wilms' Tumor Trial (WT-99) of Shanghai Children's Medical Center was designed and conducted by applying therapeutic regimens stratified by stage and histology in accordance with National Wilms' Tumor Study (NWTS) criteria of U.S.A.
  • The main aim of WT-99 was to reduce treatment of low-stage, favorable-histology (FH) tumors without impairing survival and to improve prognosis of stage III and IV (FH) and unfavorable-histology (UFH) tremors with more intensive chemotherapy.
  • METHODS: Diagnosis and treatment was decided by the multi-disciplinary team including oncologists, surgeons, pathologists, radiologists and diagnostic radiologists.
  • Patients at diffuse anaplastic stage II to IV and clear cell stage I to IV received four-drug regimen including Vcr, etoposide (VP16), Adr and cytoxan (CTX).
  • For those at rhabdoid stage I to IV the regimen was carboplatin, VP-16 and CTX.
  • Un-resectable patients received 2 courses of Ifosfamide, Vcr and VP-16 as pre-surgery therapy.
  • No radiation therapy was used for patients at stage I and FH stage II.
  • Pathologic analysis showed fourteen cases were at their FH, three at unfavorable-histology (UFH), two at clear cell and one at rhabdoid stage.
  • One relapsed after 24 months of CCR and reached the second CR after intensive chemotherapy.
  • No therapy-related death happened.
  • CONCLUSION: Multi-disciplinary team work model and protocol WT-99 are safe and effective for Wilms' tumor.
  • [MeSH-major] Kidney Neoplasms / therapy. Wilms Tumor / therapy
  • [MeSH-minor] Academic Medical Centers. Bone Transplantation. Child. Child, Preschool. China. Combined Modality Therapy. Female. Humans. Infant. Male. Neoplasm Staging. Transplantation, Autologous. Treatment Outcome


28. Rebhandl W, Handisurya A, Memaran N, Felberbauer FX, Aberle J, Paya K, Strobl B, Horcher E: Expression of cytokeratin-18-related tissue polypeptide-specific (TPS) antigen in Wilms tumor. Med Pediatr Oncol; 2001 Oct;37(4):357-64
MedlinePlus Health Information. consumer health - Wilms Tumor.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of cytokeratin-18-related tissue polypeptide-specific (TPS) antigen in Wilms tumor.
  • BACKGROUND: So far, there is no approved tumour marker for diagnosis or follow-up in Wilms tumour (WT).
  • Tissue polypeptide-specific antigen (TPS), a cytokeratin 18 proteolytic fragment, has been suggested to be of value in the clinical management of WT patients.
  • Cytokeratin 18 fragments are an early indicator of apoptosis and cytokeratin 18 might influence tumour cell behaviour.
  • We investigated TPS expression in specimens of WT and other paediatric renal malignancies PROCEDURE: Immunoreactivity of WT sections (n = 9), clear cell sarcomas (CCSK, n = 3), and a renal cell carcinoma (RCC), and two pediatric kidney tumour cell lines (WT: SK-NEP-1 and rhabdoid tumour of the kidney: G-401) were investigated using the monoclonal antibody M3.
  • Serum TPS was measured in five patients at diagnosis, during chemotherapy and after surgical resection.
  • The supernatant of G-401 but not of SK-NEP-1 showed a time- and cell number-dependent increase of TPS release.
  • CONCLUSIONS: This is the first study demonstrating the synthesis and release of TPS by WTs and other paediatric renal malignancies.
  • [MeSH-major] Biomarkers, Tumor / analysis. Keratins / metabolism. Kidney Neoplasms / metabolism. Peptides / analysis. RNA, Messenger / analysis. Wilms Tumor / metabolism

  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2001 Wiley-Liss, Inc.
  • (PMID = 11568899.001).
  • [ISSN] 0098-1532
  • [Journal-full-title] Medical and pediatric oncology
  • [ISO-abbreviation] Med. Pediatr. Oncol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Peptides; 0 / RNA, Messenger; 0 / tissue polypeptide specific antigen; 68238-35-7 / Keratins
  •  go-up   go-down


29. Perlman EJ: Pediatric renal tumors: practical updates for the pathologist. Pediatr Dev Pathol; 2005 May-Jun;8(3):320-38
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pediatric renal tumors: practical updates for the pathologist.
  • Pediatric renal tumors were targeted by the National Wilms Tumor Study Group for 4 decades with extraordinary success.
  • Within this historic context, this review provides a summary of the new Children's Oncology Group renal tumor protocols that will be opening in the very near future, focusing on their pathologic requirements.
  • All renal tumors must first be registered on the Renal Tumor Classification and Banking Protocol, followed by registration on 1 of 4 primary therapeutic protocols based on histology, stage, and molecular analysis.
  • Changes in staging criteria include classification of all tumor spillage as stage III, and requirement of regional lymph node evaluation for eligibility for stage I Wilms tumors (WTs) weighing less than 550 g in infants younger than 24 months and for stage I clear cell sarcoma.
  • Patients with unilateral favorable histology WT with loss of heterozygosity for chromosomes 1p and 16q will receive more aggressive chemotherapy at each stage.
  • Patients with bilateral WT and patients with diffuse hyperplastic perilobar nephroblastomatosis will be eligible for a novel therapeutic protocol requiring pathologic classification based on response of tumor to previous therapy.
  • Stage I anaplastic WT will be targeted with more aggressive chemotherapy than in the past.
  • For the first time, pediatric renal cell carcinoma will be eligible for a cooperative group protocol.
  • All rhabdoid tumors outside the central nervous system will be eligible for a single protocol.
  • In conclusion, these new protocols bring considerable change in their overall organization, in eligibility, and in therapy.
  • [MeSH-major] Antineoplastic Protocols. Kidney Neoplasms / therapy
  • [MeSH-minor] Child. Humans. Neoplasm Staging

  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16010493.001).
  • [ISSN] 1093-5266
  • [Journal-full-title] Pediatric and developmental pathology : the official journal of the Society for Pediatric Pathology and the Paediatric Pathology Society
  • [ISO-abbreviation] Pediatr. Dev. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 75
  •  go-up   go-down






Advertisement